Next Article in Journal
Effect of Compressive Prestrain on the Anti-Pressure and Anti-Wear Performance of Monolayer MoS2: A Molecular Dynamics Study
Previous Article in Journal
Impacts of Sol-Gel Auto-Combustion and Ultrasonication Approaches on Structural, Magnetic, and Optical Properties of Sm-Tm Co-Substituted Sr0.5Ba0.5Fe12O19 Nanohexaferrites: Comparative Study
Previous Article in Special Issue
Effect of Topography and Physical Stimulus on hMSC Phenotype Using a 3D In Vitro Model
Open AccessReview

Nanocarriers as Magic Bullets in the Treatment of Leukemia

1
Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy
2
Molecular and Preclinical Imaging Centres, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Nanomaterials 2020, 10(2), 276; https://doi.org/10.3390/nano10020276
Received: 23 December 2019 / Revised: 30 January 2020 / Accepted: 1 February 2020 / Published: 6 February 2020
(This article belongs to the Special Issue Stem Cells and Nanotechnology)
Leukemia is a type of hematopoietic stem/progenitor cell malignancy characterized by the accumulation of immature cells in the blood and bone marrow. Treatment strategies mainly rely on the administration of chemotherapeutic agents, which, unfortunately, are known for their high toxicity and side effects. The concept of targeted therapy as magic bullet was introduced by Paul Erlich about 100 years ago, to inspire new therapies able to tackle the disadvantages of chemotherapeutic agents. Currently, nanoparticles are considered viable options in the treatment of different types of cancer, including leukemia. The main advantages associated with the use of these nanocarriers summarized as follows: i) they may be designed to target leukemic cells selectively; ii) they invariably enhance bioavailability and blood circulation half-life; iii) their mode of action is expected to reduce side effects. FDA approval of many nanocarriers for treatment of relapsed or refractory leukemia and the desired results extend their application in clinics. In the present review, different types of nanocarriers, their capability in targeting leukemic cells, and the latest preclinical and clinical data are discussed. View Full-Text
Keywords: nanocarrier; nanosystem; nanoparticle; liposome; leukemia; AML; ALL; CLL; CML; targeted therapy nanocarrier; nanosystem; nanoparticle; liposome; leukemia; AML; ALL; CLL; CML; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Houshmand, M.; Garello, F.; Circosta, P.; Stefania, R.; Aime, S.; Saglio, G.; Giachino, C. Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials 2020, 10, 276.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop